Page 3 - Adjuvant Setting News Today

Investigators report the first phase 3 results for a radiosensitizing alternative to cisplatin for patients who cannot tolerate it.

The agency expanded the indication for pembrolizumab to the adjuvant setting for patients with stage IB-IIIA NSCLC following surgery and platinum-based chemo.

The new research brings data to an area of ambiguity, but the findings come with caveats.

With no overall survival benefit thus far, plus other concerns, editorialists "urge caution" before accepting abemaciclib as a standard of care in early breast cancer without mature data.

The findings shed light on a contentious debate. The study was published as a preprint and has not yet been peer reviewed.

The US Food and Drug Administration has approved zonisamide oral suspension (Zonisade) as adjunctive therapy for partial seizures in adults and teens 16 years and older with epilepsy.

Discussing adjuvant pembrolizumab in KEYNOTE-716, one expert said, This is a bitter pill to swallow because youre treating people longer and youre not sure if youre really helping them.

Compared with open surgery, patients who underwent laparoscopic surgery for rectal cancer had significantly improved 5-year overall survival.

A new analysis found that "Black patients are less likely than White patients to receive standard of care" when undergoing surgery to treat gastrointestinal tract cancer.

Further data from the pivotal Checkmate 816 trial continue to support the combination of nivolumab with chemotherapy in the neoadjuvant setting for patients with resectable non–small cell lung cancer.